- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- March 2024
- 185 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 175 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 250 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- January 2024
- 200 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- November 2023
- 175 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- February 2024
- 110 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- April 2024
- 190 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- November 2023
- 181 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- October 2023
- 190 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- October 2023
- 189 Pages
Global
From €4724EUR$4,900USD£4,040GBP
- Report
- August 2023
- 295 Pages
Global
From €9159EUR$9,500USD£7,833GBP
- Report
- June 2023
- 118 Pages
Global
From €4338EUR$4,500USD£3,710GBP
- Report
- March 2018
- 300 Pages
Global
From €2314EUR$2,400USD£1,979GBP
- Report
- April 2024
- 318 Pages
From €5264EUR$5,651USD£4,350GBP
- Report
- July 2022
- 461 Pages
Global
From €4780EUR$5,132USD£3,950GBP
- Report
- October 2022
- 270 Pages
Global
From €3615EUR$3,750USD£3,092GBP
Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more